WHOCC
Postal address:
WHO Collaborating Centre for Drug Statistics Methodology
Norwegian Institute of Public Health
Postboks 222 Sk°yen
0213 Oslo
Norway

Visiting/delivery address:
Sandakerveien 24C
Bygg C
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

Alterations in ATC/DDD

Lists of ATC/DDD alterations decided at the latest meeting of the WHO International Working Group for Drug Statistics Methodology. Comments or objections to the ATC/DDD alterations should be forwarded to the WHO Collaborating Centre for Drug Statistics Methodology within the deadline. If no objections are received, the alterations will be considered final and included in the ATC/DDD Index. The year of implementation in the ATC/DDD Index is given in the list. 

Please note that all ATC and DDD alterations are valid and implemented annually.

Change in ATC codes

INN/generic namePrevious ATC codeNew ATC codeDeadline for objection to temporary alterations Implementation in ATC/DDD index
No alterations.

Change of ATC level name

Previous nameNew ATC level nameATC codeDeadline for objection to temporary alterations Implementation in ATC/DDD index
metronidazole, combinationsmetronidazole and furazolidoneP01AB5101.02.20212022
proguanil, combinationsproguanil and atovaquoneP01BB5101.02.20212022
Triazole derivativesTriazole and tetrazole derivativesJ02AC01.02.20212022

Change of ATC code and/or ATC level name based on new ATC 4th levels established

Previous ATC code and level nameNew ATC code and/or level name
R06AA02 1)diphenhydramineR06AA11 dimenhydrinate01.02.20212022
1) Splitting of ATC code. Products containing dimenhydrinate (rINN)/diphenhydramine teoclate are moved to the new code. Product containing diphenhydramine chloride will remain in R06AA02.

Change of DDDs

ATC codeLevel namePrevious DDDNew DDDDeadline for objection to temporary alterations Implementation in ATC/DDD index
No alterations.

Last updated: 2020-12-14